Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Glaucoma
Phase NA
Enrollment 60
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multi-center, international, cohort expansion study. Part 1 will be conducted in subjects with open angle glaucoma to identify the best insertion tool for MINIject S+. In Part 1, three different investigational insertion tools will be used to place MINIject implants in this first-in man study. Each arm represents a different version of the insertion tool. Subject and independent central reader will be blinded to the insertion tool used to implant MINIject S+. Part 2 will be an expansion phase where the selected insertion tool will be assessed in a larger population of subjects with open angle glaucoma and operable cataracts undergoing combined glaucoma and cataract surgery (with IOL implantation).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: MIGS — Implant MINIject S+ in supraciliary space

Primary Outcomes

  • Number of patients with correct placement of the device in the supraciliary space, as assessed by the blinded central reader (1 week)
  • Ease of use evaluation (during the surgery procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-29
Completion: 2028-07
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: iSTAR Medical
Contact Information
Study Contact:
Delphine Hanot Mambres, PhD
0032472384955
delphine.hanot@istar-medical.com
Sabine Glibert
0032476609408
sabine.glibert@istar-medical.com
Marco Robles, Doctor
0050426622028
marock28@gmail.com
Los Robles Vision d/b/a Centro Oftalmológico Robles
Interventions
  • Device: MIGS — Implant MINIject S+ in supraciliary space
Study Locations (5 sites)
Los Robles Vision d/b/a Centro Oftalmológico Robles, Santa Rosa de Copán, 41101 Honduras
Colchester General Hospital, Colchester, CO45JL United Kingdom
Diana, Princess of Wales Hospital, Grimsby, DN33 2 United Kingdom
Royal Liverpool University Hospital, Liverpool, L7 3 United Kingdom
St Thomas' Hospital, London, SE17EH United Kingdom
Eligibility Criteria
Inclusion criteria 1. Males or females, 20 years of age or older 2. Diagnosis of open angle glaucoma (OAG) in the study eye 3. Iridocorneal angle grade 3 (open, 20-35 degrees) or grade 4 (wide open, 35-45 degrees) according to Shaffer Angle Grading System in all quadrants of the study eye. (For subject's undergoing combined cataract extraction (with IOL implantation) with MINIject implantation, a grade 2 angle is acceptable prior to cataract surgery so long is the angle becomes grade 3 or greater prior to MINIject implantation). 4. Glaucoma not adequately controlled with at least one topical hypotensive medication(s), unless the subject has an allergy / intolerance to a medication or inability to consistently access medication. Examples include but are not limited to prostaglandins, beta blockers, carbonic anhydrase inhibitors or alpha-2-agonists 5. Minimal visual acuity in the study eye must be 35 letters EDTRS (20/200) or better and 50 letters ETDRS (20/100) or better in the fellow eye 6. Maximal C/D ratio must be 0.9 in the study eye 7. Subjects must be willing and able to follow study instructions and to return for scheduled study-related examinations 8. Subjects must provide written informed consent prior to any study procedures 9. Part 2 Only: Operable age-related cataract eligible for phacoemulsification surgery with Intraocular Lens (IOL) implantation 10. Part 2 Only: The following intraoperative criteria following the IOL implantation need to be met in order for investigator to proceed with the investigational device placement: 1. Capsulorhexis is intact and centered 2. Posterior capsular bag is intact 3. The IOL is well-centered in the capsular bag 4. There is no evidence of zonular dehiscence/rupture 5. The Anterior Chamber (AC) angle was able to be clearly visualized using direct gonioscopy. Exclusion criteria Subjects are not eligible for inclusion in this clinical investigation if one or more of the following criteria are met: 1. Grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees) and grade 0 (closed or slit) iridocorneal angle according to Shaffer Angle Grading System in the study eye except for the situation described in inclusion criterion #3. 2. Any eye surgery that was performed \< 90 days before Screening/Baseline visit in the study eye 3. Diagnosis of diabetes mellitus with HbA1C \>7% 4. Known or suspected allergy or hypersensitivity to medical silicone 5. Allergy to fluorescein 6. Corneal opacity or iridocorneal angle not visible through gonioprism in the study eye, preventing correct placement of the implant 7. Central endothelial cell density (ECD) at Screening visit with a mean value \<1900 cells/mm2 or coefficient of variation (CV) of endothelium \>0.45 A variance of 5% less than this cell count is permitted if in the clinical judgement of the Investigator the potential benefit/risk to subject participation is favorable and the central corneal endothelial morphology is characterized as normal by the usual criteria of hexagonality, polymorphism, and polymegathism 8. Anticipated need for ocular surgery or retinal laser procedure in the study eye 9. Anterior chamber anatomic configuration of high risk for development of angle closure glaucoma in the study eye, 10. Pre-existing ocular or systemic pathology that, in the opinion of the investigator (reason to be specified on the case report form), is likely to cause post-operative complications following implantation 11. Central corneal thickness greater than 600 microns 12. Clinically significant degenerative visual disorders that, in the opinion of the investigator, can impact study examinations (e.g. exudative macular degeneration or other retinal disorders) 13. Clinically significant corneal disease (e.g., corneal dystrophy) in the study eye 14. Evidence of crystalline lens subluxation or luxation in the study eye 15. Inability to perform Visual Field (VF) testing in either eye 16. Evidence of vitreous loss in the anterior chamber in the study eye 17. Clinically significant intra-ocular inflammation or infection 18. Presence of silicone oil in the study eye 19. Participation in any study involving a drug or device within the past 3 months and planned participation to any other study during the present study. There is no exclusion period after completion of the present trial 20. Only for women of childbearing potential: positive pregnancy test at Screening/Baseline visit. Pregnant or lactating women 21. Subject is under tutorship or trusteeship 22. Subject has a condition such that his / her ability to provide personal informed consent is compromised 23. Diagnosis of cataract in the study eye that is not age-related e.g., traumatic, inflammatory or resulting from diabetes in the study eye 24. Unable to discontinue anticoagulant/antiplatelet therapy (i.e. acetylsalicylic acid, coumadin, heparin, apixaban, etc.) for the surgical procedure. The amount of washout and when to restart therapy after surgery is at the Principal Investigator's discretion and may be based on literature references (see Annexes) or in consultation with the subject's primary care team.
Conditions Group 3 Pulmonary Hypertension
Phase PHASE2
Enrollment 126
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat. The main question it aims to answer is if mirivadelgat will improve pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a way to measure blood flow in the lungs. Researchers will compare mirivadelgat to a placebo (a look-alike capsule that contains no drug) to see if mirivadelgat works to improve the symptoms of PH-ILD. The symptoms of PH-ILD that are being looked at are exercise tolerance, heart function, and general well-being. Participants will: Take mirivadelgat or a placebo once a day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Receive phone calls every one or two weeks to check on how things are going

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Mirivadelgat — Selective aldehyde dehydrogenase 2 (ALDH2) activator
  • Drug: placebo — placebo

Primary Outcomes

  • Pulmonary Vascular Resistance (PVR) (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-01
Completion: 2028-02
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.
Collaborators: QPS Holdings LLC
Principal Investigators:
  • Bassem Elmankabadi, MD (STUDY_DIRECTOR) - Foresee Pharmaceuticals
Contact Information
Study Contact:
Bassem Elmankabadi, MD
+1 562-310-8718
Bassem.elmankabadi@foreseepharma.com
Yisheng Lee, MD
408-823-4807
yisheng.lee@foreseepharma.com
Wei-Tung Lin
866-988431106
tonton711223@gmail.com
Hualien Tzu Chi Hospital
Interventions
  • Drug: Mirivadelgat — Selective aldehyde dehydrogenase 2 (ALDH2) activator
  • Drug: placebo — placebo
Study Locations (11 sites)
University Clinical Centre of the Republic of Srpska, Banja Luka, 78000 Bosnia and Herzegovina
Clinical Center of the University of Sarajevo, Sarajevo, 71000 Bosnia and Herzegovina
Hualien Tzu Chi Hospital, Hualien City, Taiwan 970 Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan Taiwan
Taichung Veterans General Hospital, Taichung, Taiwan 407219 Taiwan
National Cheng Kung University Hospital, Tainan, Taiwan 704 Taiwan
National Taiwan University Hospital, Taipei, Taiwan 100225 Taiwan
Taipei Veterans General Hospital, Taipei, Taiwan 11217 Taiwan
Chang Gung Memorial Hospital - Linkou Branch, Taoyuan City, Taiwan Taiwan
Kaohsiung Veterans General Hospital, Kaohsiung City, 813 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. A clinical diagnosis of PH-ILD. 2. Participant voluntarily gives informed consent. 3. Male or female participants aged between 18 and 85 years at the time of signing informed consent. 4. Participants must agree to practice protocol-defined birth control during the study period, unless they meet criteria for not being of childbearing potential. * Male participants with female partners of childbearing potential must practice protocol- defined birth control for the duration of treatment and at least 96 hours after discontinuing the IP. * Female participants of childbearing of potential (including those \<1-year post-menopausal) must practice protocol-defined birth control during the conduct of the study and for 30 days after the last dose of IP (males only during exposure to IP). * Female participants not of childbearing potential (as defined below) are eligible for enrolment without contraception requirements: 1. Post-menopausal women (at least 12 months with no menses without an alternative medical cause); in women \<45 years of age, a high follicle-stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy; OR 2. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR 3. Have a congenital or acquired condition that prevents childbearing. 5. The participant has a confirmed diagnosis of any form of interstitial lung disease based on high-resolution computed tomography (HRCT) of the chest within 180 days prior to screening or at screening or a historical surgical biopsy (or other appropriate tissue sampling (e.g., cryobiopsy). The participant can have other findings (e.g., emphysema) if this is not the predominant feature on the scan. 6. Participants have undergone RHC during the screening period with the following documented parameters: * Pulmonary vascular resistance (PVR) ≥4 Wood units and * Pulmonary capillary wedge pressure (PCWP) of ≤12 mmHg \[if PVR ≥4 Wood units to \<6.25 Wood units\] or PCWP ≤15 mmHg \[if PVR ≥6.25 Wood units\] Note: If a reliable PCWP cannot be obtained, left ventricular end-diastolic pressure (LVEDP), measured via left heart catheterization (LHC), will be acceptable, with the same numerical thresholds as the PCWP criterion: LVEDP of ≤12 mmHg \[if PVR ≥4 to \<6.25 Wood units\], or LVEDP ≤15 mmHg * A mean pulmonary arterial pressure (PAP) of \>20 mmHg. 7. Participants must have a 6-minute walk distance ≥100 meters and ≤500 meters at the Screening Visit (Visit 1). 8. Participants agree to a repeat RHC, Chest CT, and MRI prior to study completion. 9. Participants on chronic treatment for underlying lung disease (i.e., nintedanib or pirfenidone or immunosuppressive agents etc.) must be on a stable/optimized dose for ≥30 days prior to screening and have been receiving treatment for ≥90 days. 10. Participants on supportive medications (e.g., inhalers for asthma) must be on stable doses for ≥30 days prior to screening. 11. In the Investigator's opinion, the participant must be able to consent for themselves and communicate with local staff using interpreters if necessary. Participants must agree to attend all study visits and be contactable through a cellular device or landline. 12. Participants must have clinical laboratory values within normal ranges or \<1.5 times the upper limit of normal (ULN) as specified by the testing laboratory. 13. Participants must meet the following requirements for the pulmonary function test (PFT) at screening: * Forced vital capacity (FVC) \<90% of predicted * Diffusion capacity of carbon monoxide (DLCO) \<70% of predicted, or \<70% of predicted corrected for hemoglobin (Hb), if correction is required. (Correction applies if Hb value is ≥25% and ≤90% of normal.) Note: DLCO must be determined locally at screening, using American Thoracic Society (ATS) standards. Hemoglobin correction should reference ATS normal values: Men = 14.6 g/dL, Women = 13.4 g/dL. 14. Negative serology test for hepatitis B surface antigen and hepatitis C antibody at Screening Visit. Exclusion criteria: Medical Conditions 1. Participant has another concomitant diagnosis of pulmonary hypertension not otherwise considered to be PH-ILD. This would include and is not limited to the concomitant presence of thromboembolic disease, untreated/inadequately treated obstructive sleep apnea, human immunodeficiency virus (HIV), methamphetamine or anorexigenic drug use, and other conditions of the WHO Group 1, 2, 4, and 5 classifications. 2. Participant has evidence of clinically significant left-sided heart disease within 6 months of screening as defined by: * Left ventricular ejection fraction \<40% as assessed by echocardiography. * More than mild left-sided valvulopathy (e.g., worse than mild mitral stenosis or regurgitation and worse than mild aortic stenosis or regurgitation). * LVEDP or PCWP \>15 mmHg (or \>12 mmHg if PVR ≥4 to 6.25 Wood units). 3. Participants must NOT have 3 or more of the following left ventricular disease/dysfunction risk factors at screening: * Body mass index (BMI) ≥30 kg/m2. * Uncontrolled diabetes, as evidenced by HbA1C \>9.5%, or urine glycosuria \>1.0 g/dl, or presence of diabetic ketoacidosis. * History of significant coronary disease within 6 months of screening as demonstrated by any of the following: 1. History of myocardial infarction or acute coronary syndrome (unstable angina), or 2. Percutaneous coronary intervention or percutaneous transluminal angioplasty, or previous coronary artery bypass graft, or 3. Evidence of coronary artery disease (\>50% stenosis in at least one major coronary artery) or abnormal nuclear stress test. 4. The participant is receiving ≥10 L/min of oxygen supplementation by any mode of delivery at rest. 5. The participant has received any PH-approved therapy, including soluble guanylate cyclase inhibitors, endothelin receptor antagonists, or parenteral or oral prostacyclin therapy (excluding vasoreactivity testing) within 60 days of randomization or 5 half-lives. Use of phosphodiesterase type 5 inhibitors and inhaled prostacyclin (e.g., inhaled treprostinil) on stable doses for ≥30 days prior to screening will be allowed irrespective of local approval (as per ESC/ERS 2022). 6. Use of any inhibitors and inducers of cytochrome P450 3A4 (CYP3A4) (e.g., boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, telithromycin, troleandomycin, voriconazole, clarithromycin, idelalisib, nefazodone, nelfinavir, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort). For a comprehensive list, please refer to the FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems (FDA 2025). 7. Recent exacerbation of underlying lung disease or active pulmonary/upper respiratory tract infection within 4 weeks of randomization. 8. Any current active malignancy (this does not include localized cancers such as basal or squamous cell carcinoma of the skin). Any history of malignancy that is likely to result in mortality or require significant medical or surgical intervention within the following year. 9. Chronic kidney disease Stage IV or greater (i.e., eGFR ˂30 mL/min/1.73m2) or evidence of acute kidney injury. 10. The participant has a history of congenital heart disease, irrespective of any prior treatment or surgical intervention 11. Use of tobacco, e-cigarette, nicotine, or marijuana products or a significant history of drug or alcohol abuse within 6 months of screenin
Conditions Advanced Breast Cancer, Advanced Gastric...
Phase PHASE2
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Procedure: Biological samples collection — Biological samples collection (tumor tissue, blood, sputum) before initiation of treatment, during treatment, and at treatment discontinuation.
  • Behavioral: questionnaires to collect patient reported outcomes — QLQ-C30, QLQ-FA12, HADS, EQ-5D 5L

Primary Outcomes

  • Biomarkers of resistance to ADC (Through study completion, an average of 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-14
Completion: 2030-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNICANCER
Principal Investigators:
  • Barbara Pistilli, MD, PhD (PRINCIPAL_INVESTIGATOR) - Gustave Roussy Cancer Center
Contact Information
Study Contact:
Marjorie Mauduit
+33 6 30481792
m-mauduit@unicancer.fr
Jérôme Lemonnier
j-lemonnier@unicancer.fr
Barbara PISTILLI, MD
+33 (0)1 42 11 61 62
barbara.pistilli@gustaveroussy.fr
Gustave Roussy Cancer Center
Interventions
  • Procedure: Biological samples collection — Biological samples collection (tumor tissue, blood, sputum) before initiation of treatment, during treatment, and at treatment discontinuation.
  • Behavioral: questionnaires to collect patient reported outcomes — QLQ-C30, QLQ-FA12, HADS, EQ-5D 5L
Study Locations (1 sites)
Gustave Roussy Cancer Center, Villejuif, 94805 France
Eligibility Criteria
Inclusion Criteria: 1. Patients must have signed a written informed consent form prior to any trial specific procedures; 2. Patients must be ≥18 years old; 3. Histologically confirmed or radiologically documented unresectable locally advanced or metastatic cancer (Breast, Urothelial, Non small Cell Lung or Gastric) with an indication to receive an Antibody-Drug Conjugate (ADC) approved or accessible through an early access program; 4. Patients must have at least 2 tumor lesions (primary tumor can be included): at least one measurable tumor lesion for tumor evaluation according to response evaluation criteria in solid tumors (RECIST) V1.1 and at least one tumor lesion other than bone and brain for biopsy; 5. Patients must have a metastatic or locally advanced tumor site easily accessible to biopsy (with exception of bone and brain metastasis) and must have agreed to perform pretreatment and post-treatment biopsies; an archival pre-treatment biopsy may be used if it was collected within one month of enrolment, if no anticancer therapy was administered after the biopsy and if sufficient material is available for research; 6. Life expectancy must be ≥12 weeks according to the discretion of the investigator; 7. ECOG performance status ≤ 2; 8. Patients must have adequate hematologic and organ function, compatible with ADC administration, as per drug-specific recommendations; 9. Women of childbearing potential and male patient must agree to use adequate contraception for the duration of trial participation and up to 7 months after completing treatment for women and up to 4 months for men; 10. Patients must be affiliated to a social security system (or equivalent); 11. Patients must be willing and able to comply with the protocol for the duration of the trial; 12. Patients must consent to the use of their collected tumor specimen, as well as, blood samples as detailed in the protocol for future scientific research, which includes but is not limited to DNA, RNA, and protein-based biomarker analysis. Exclusion Criteria: 1. Patients treated with an antibody drug conjugate in a curative setting; 2. Patients who did not consent to sample use; 3. Presence of another progressive pathology with short-term life-threatening prognosis; 4. Patients undergoing concurrent treatment for a malignancy or hematologic disorder distinct from the indication for which the ADC is being administered. 5. Patients with inadequate washout period prior to Cycle 1 Day 1, defined as: * Whole brain radiation therapy \<14 days or stereotactic brain radiation therapy \<7 days. * Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) (including another ADC) from a previous cancer treatment regimen or clinical study (other than epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)), \<14 days or 5 half-lives, whichever is longer. * Immune checkpoint inhibitor therapy \<21 days. * Hormonal therapy \<21 days. * Major surgery (excluding placement of vascular access) \<28 days. * Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation \<28 days or palliative radiation therapy \<14 days. 6. Female participant who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 90 days after the final administration of study treatment; 7. Person deprived of their liberty or under protective custody or guardianship.
Conditions Breast Cancer Metastatic, Advanced Breas...
Phase NA
Enrollment 100
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pilot study is to understand and improve the shared decision-making process between people with advanced breast cancer and their providers regarding their care and treatment. As part of this study, the researchers will evaluate a decision support tool called COAST that was designed to support patients and providers in having meaningful conversations. The main questions it aims to answer are: 1. Can the COAST tool improve the quality of communication between patients and their oncology providers? 2. Is the COAST tool acceptable, appropriate, and easy to use at NYP-Weill Cornell Medicine, NYP-Brooklyn Methodist Hospital and NYP-Queens? Participants will be asked to fill out two surveys: one before they use the COAST tool and another about 2 - 4 weeks later. Some patients will also be invited for an interview.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Decision Support Tool — The COAST decision support tool will be available in two formats: a booklet and a website. It will provide information about advanced breast cancer and the available treatment options. Participants will be guided through questions designed to clarify their goals and preferences, identify support needs, and concerns they may have.

Primary Outcomes

  • Patient-reported acceptability of the COAST decision support tool (2-4 weeks after exposure to COAST)
  • Patient-reported appropriateness of the COAST decision support tool (2-4 weeks after exposure to COAST)
  • Provider-reported feasibility of the COAST decision support tool (At the conclusion of participant enrollment, approximately 1 month after the last patient is enrolled.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-17
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: Gilead Sciences
Principal Investigators:
  • Shoshana Rosenberg, ScD, MPH (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Zori K Hamilton, MA
646-962-3694
zkh4001@med.cornell.edu
Darima Dorzhieva
646-962-8666
dad4011@med.cornell.edu
Zori K Hamilton, MA
6469623694
zkh4001@med.cornell.edu
NewYork-Presbyterian Brooklyn Methodist Hospital
Interventions
  • Behavioral: Decision Support Tool — The COAST decision support tool will be available in two formats: a booklet and a website. It will provide information about advanced breast cancer and the available treatment options. Participants will be guided through questions designed to clarify their goals and preferences, identify support needs, and concerns they may have.
Study Locations (3 sites)
NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York 11215 United States
NewYork-Presbyterian Medical Group Queens, Flushing, New York 11355 United States
NewYork-Presbyterian David H. Koch Center, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Male or female 18 years and older * Diagnosis of Stage IV breast cancer * English, Spanish or Mandarin speaking Exclusion Criteria: * Early breast cancer * Individuals speaking languages other than English, Spanish, or Mandarin as their primary language
Conditions Brain Metastases, Adult, Breast Cancer
Phase NA
Enrollment 42
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast cancer has spread to the brain (brain metastases) at 8 weeks post enrolling into the study. The main questions that have been set out to to answer are: * Is it possible to deliver the novel radiotherapy approach, DE-iPTV? * Is it possible to measure health -related quality of life? * What impact does the novel radiotherapy approach have on: patient's quality of life, control of the brain metastasis (control of the lesion) and steroid use? Participants will: * Receive 5 doses of radiotherapy * Complete weekly quality of life (EQ-5D) assessments and medication (steroid) diaries (via telephone/ postal) until 12 weeks post enrolment * Be reviewed in clinic with up-to-date MRI scans at 8, 12 and 24 weeks post-enrolment * Complete a more detailed HRQoL panel of assessments will be assessed at baseline, 8 weeks, 12 weeks and 24 weeks post enrolment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: DE-iPTV — Dose-escalated VMAT-based radiotherapy, as previously described in our planning study

Primary Outcomes

  • Feasibility of delivering DE-iPTV and measuring health related quality of life questionnaire in patients with brain metastases from breast cancer to whom their treating clinician would normally offer whole brain radiotherapy (8 weeks post-enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2028-06
Eligibility
Age: 16 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Imperial College London
Collaborators: University of Leicester, Centro Nacional de Investigaciones Oncologicas CARLOS III, East and North Hertfordshire NHS Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust, Imperial College Healthcare NHS Trust
Contact Information
Study Contact:
Lillie Pakzad-Shahabi, BSc MSc
02033118427
beat-breast@imperial.ac.uk
Matt Williams, FRCR PhD
02033118427
matthew.williams@imperial.ac.uk
Lillie Pakzad Shahabi, BSc MSc
beat-breast@imperial.ac.uk
Imperial College London
Interventions
  • Radiation: DE-iPTV — Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
Study Locations (2 sites)
Imperial College London, London, London SW7 2AZ United Kingdom
University of Oxford Cancer and Haematology Centre | Churchill Hospital Headington, Oxford,, Oxford, OX3 7LE United Kingdom
Eligibility Criteria
Inclusion Criteria 1. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up 2. Adult (aged 16+) patients, resident in the United Kingdom. 3. Histologically confirmed primary breast cancer with brain metastases on MRI imaging 4. The treating oncologist considers whole-brain radiotherapy to be the most suitable treatment outside of the trial. 5. Eastern Cooperative Oncology Group Performance status 0, 1 or 2 6. Able to respond to question about their quality of life, symptoms, and side effects remotely (via telephone assessments 7. Life expectancy from extra-cranial disease \>3 months Exclusion Criteria 1. Leptomeningeal disease 2. "Miliary" pattern of metastases: patients with over 15 metastases are excluded (clinician-based assessment) 3. Cystic metastases 4. Previous whole or partial brain radiotherapy (previous surgery or SRS is acceptable) 5. Plan for hippocampal-sparing whole brain radiotherapy. 6. Unable to give informed consent. 7. Prognosis less than 3 months 8. Pregnant or nursing women 9. Unable to complete a brain MRI and/or known allergy to gadolinium.

Quilting Sutures After Mastectomy

NCT06415032
Recruiting
Conditions Breast Cancer
Phase NA
Enrollment 296
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The use of wound drains after mastectomy is common practice in Belgium. However, placement of suction drainage has several disadvantages. Skin bacteria can enter via the drain and cause infection, or the drain itself can cause discomfort and a need for daily nursing. After drain removal, seroma is the most common complication following breast cancer surgery. Seromas are collections of serous fluid that frequently develop under the skin or in the axillary space formed after mastectomy and/or axillary lymph node dissection, resulting from surgical trauma to blood/lymphatic vessels and post-traumatic inflammation. Seroma formation can cause discomfort and limitations in shoulder function. Moreover, it is associated with surgical site infections, often requires treatment and increases healthcare consumption. Wound healing problems might be a cause of postponement of adjuvant therapy. The quilting suture technique, in which the skin is sutured to the pectoralis muscle and drain placement is not needed, may lead to a significant reduction of seroma with a decrease in the number of aspirations and surgical site infections. In this national multicentric study, we will compare mastectomy with placement of suction drains, a standard technique used in the vast majority of Belgian hospitals, with the new quilting suture technique without placement of suction drains. We will focus on 3 distinct primary outcomes: * Pain of the mastectomy area 6 months after surgery * Upper limb function 6 months after surgery * Cosmetic outcome scored by the patient 6 months after surgery. The goal of this study is to demonstrate the absence of long-term negative effects of the quilting suture technique on shoulder function, cosmetic outcome, and pain management.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Mastectomy with Quilting sutures without drain placement — The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
  • Procedure: Mastectomy with Conventional sutures with drain placement — The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time

Primary Outcomes

  • Pain in the mastectomy area scored by VAS (6 months postoperative)
  • Upper limb function scored by QuickDASH (6 months postoperative)
  • Cosmetic outcome scored by the patient on a 10-point scale (6 months postoperative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-23
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 296 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitaire Ziekenhuizen KU Leuven
Collaborators: Belgium Health Care Knowledge Centre
Principal Investigators:
  • Ann Smeets, MD,PhD (PRINCIPAL_INVESTIGATOR) - UZ Leuven
Contact Information
Study Contact:
Hanne Vos, PhD
016340903
hanne.vos@uzleuven.be
Surgical Oncology, UZ Leuven
Ann Smeets, MD, PhD
Surgical Oncology, UZ Leuven
Interventions
  • Procedure: Mastectomy with Quilting sutures without drain placement — The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
  • Procedure: Mastectomy with Conventional sutures with drain placement — The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
Study Locations (1 sites)
Surgical Oncology, UZ Leuven, Leuven, 3000 Belgium
Eligibility Criteria
Inclusion Criteria: * capable of giving written informed consent * age ≥ 18 years * scheduled for unilateral mastectomy without immediate breast reconstruction with or without axillary surgery (sentinel lymph node biopsy or axillary lymph node dissection) Exclusion Criteria: * scheduled for mastectomy with immediate breast reconstruction * scheduled for synchronous bilateral breast and/or axillary surgery
Conditions Breast Cancer, Pancreatic Cancer, Pulmon...
Phase EARLY_PHASE1
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to develop a new cancer diagnostic and prognostic tool based on the dynamic and non-invasive detection of an exogenous volatile molecule, i.e., ethanol, from patients' samples. Patients' blood plasma will be analyzed with a mixture of volatile organic compound-based probes, each targeting a specific glycosidase. The presence of a given glycosidase in a blood sample would thus be revealed by the detection of an ethanol isotope in the gas phase. 3 groups of patients with localized cancer (breast, prostate, pancreas) will be enrolled, as well as 1 group of patient without any cancer (control group). For the patients, two 5ml plasma samples will be collected, one before and one after surgery for localized cancers. For healthy volunteers, only one 5ml plasma sample will be collected. The primary objective will be to compare the levels of glycosidases measured in the blood of patients followed for localized cancer and referred for first surgery compared to control patients without cancer.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Biological: blood plasma sample — For each patient, 5ml blood sample will be needed before the surgery and another 5ml blood sample one month after the surgery.
  • Biological: blood sampling — 5ml blood sample for control arm

Primary Outcomes

  • To compare the levels of glycosidases measured in the blood samples of patients treated for a localized cancer (breast, lung or pancreatic cancer) compared to control patients without cancer. (before surgery and one month after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2026-02-03
Completion: 2028-03-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Poitiers University Hospital
Contact Information
Study Contact:
Sheik Emambux, MD PhD
+33549444279
sheik.emambux@chu-poitiers.mssante.fr
Sheik EMAMBUX, MD
+33549444279
sheik.emambux@chu-poitiers.fr
C.H.U. Poitiers
Interventions
  • Biological: blood plasma sample — For each patient, 5ml blood sample will be needed before the surgery and another 5ml blood sample one month after the surgery.
  • Biological: blood sampling — 5ml blood sample for control arm
Study Locations (1 sites)
C.H.U. Poitiers, Poitiers, 86000 France
Eligibility Criteria
Inclusion Criteria: * Group 1: 40 patients with definitively diagnosed, untreated, localized solid breast cancer referred for initial surgical treatment. Group 2: 40 patients with definitively diagnosed, untreated, localized solid lung cancer referred for initial surgical treatment. Group 3: 40 patients with definitively diagnosed, untreated, localized solid pancreatic cancer referred for initial surgical treatment. Group 4: 100 control patients with no cancer diagnosis or history of solid or hematological cancer. Exclusion Criteria: * Refusal to participate in the research. * Patients benefiting from enhanced protection, namely: minors, pregnant/breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a social care facility, adults under legal protection Specific criteria for groups 1, 2, and 3: * Cancer patients undergoing oncological treatment. * Cancer not proven by anatomopathological examination.
Conditions Breast Cancer, Ovarian Cancer, Endometri...
Phase PHASE1
Enrollment 9
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. The main questions it aims to answer are: * Does the investigational drug BL0175 is safe for participants after dosed -multiple times? * Which is the highest safety dose of BL0175 after multiple dose? * What medical problems do participants have when using BL0175? * Does the investigational drug BL0175 works for participants after dosed -multiple times?

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL0175 — BL0175 is a nano-medicine for cancer therapy. "Nano-medicine" means the tiny size of this study drug allows it to enter and concentrate into the tumor tissue. This is a new way of delivering an active drug (an estrogen receptor down regulator) for the treatment of tumor directly into tumor tissue.

Primary Outcomes

  • Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0 (From enrollment to the end of treatment at 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-03-10
Completion: 2027-12-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 9 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Best-Link Bioscience, LLC
Contact Information
Study Contact:
Guat Hoon Ong
+65 9726 6883
gho@zhangjiang-bio.com
Haiyan Jia
+86 0431-88782705
jiahaiyan0317@qq.com
The First Hospital of Jilin University
Meili Sun
+86 0531-55865775
smli1980@163.com
Jinan Central Hospital
Interventions
  • Drug: BL0175 — BL0175 is a nano-medicine for cancer therapy. "Nano-medicine" means the tiny size of this study drug allows it to enter and concentrate into the tumor tissue. This is a new way of delivering an active drug (an estrogen receptor down regulator) for the treatment of tumor directly into tumor tissue.
Study Locations (2 sites)
The First Hospital of Jilin University, Changchun, Jilin 130000 China
Jinan Central Hospital, Jinan, Shandong 250000 China
Eligibility Criteria
Inclusion Criteria: 1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and willingness to sign a written informed consent form. 2. Age ≥ 18 years. 3. HR-positive, HER2-negative (characterized by the absence of HER2 expression and the presence of ER and/or PR expression) locally advanced or metastatic breast cancer (histological or cytological proven diagnosis) in postmenopausal women with disease progression during or following endocrine therapy, or HR-positive, locally advanced or metastatic ovarian cancer or endometrial cancer in postmenopausal women that progressed during or following prior standard of care therapy. 4. Patients with at least one measurable or evaluable lesion: At least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/plain x-ray at baseline and follow up visit. Note: Measurable lesions cannot be selected from the following sites in principle: having received prior radiotherapy or having received other local therapy. If a target lesion at a site that has received prior radiotherapy or other local therapy is the only optional lesion, the progression of the lesion shall be confirmed by the investigator. 5. Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 at screening. 6. Life expectancy period ≥ 12 weeks. Exclusion Criteria: 1. Patients with symptomatic central nervous system (CNS) metastases or carcinomatous meningitis. Note: patients with treated CNS metastases may participate in this study if the patient has completed radiotherapy or surgery for CNS metastases ≥ 4 weeks prior to study entry, and if the patient is neurologically stable ≥ 2 weeks after radiotherapy or surgery treatment (no new neurologic deficits from brain metastasis on screening clinical examination, no new findings on CNS imaging, and corticosteroids were not required within 2 weeks prior to enrollment). 2. Patients who have a history of another primary malignancy (with the exception of participants with cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix). A patient who has had no evidence of disease from another primary cancer for 3 or more years is allowed to participate in the study. 3. Patients whose pericardial effusion, pleural effusion or ascites remain uncontrollable after intervention. 4. Patients with a history of allogeneic transplantation of organs, bone marrow or stem cell. 5. A history of allergic or adverse response(s) to fulvestrant, or prone to allergic reactions (such as: prone to angioedema, urticaria, asthma, rash, etc.). 6. Patients who have impaired cardiac function or clinically significant cardiac diseases, including any of the following: * New York Heart Association class III-IV for cardiac insufficiency or left ventricular ejection fraction \< 50% (if the LVEF data is available). * Patients with poorly controlled arrhythmia: QTc interval \> 480 ms calculated by Fridericia's formula, or congenital syndrome of prolonged QT interval. * Any of the following within 6 months prior to the enrollment: myocardial infarction, severe or unstable angina, congestive heart failure, cerebrovascular accident (including transient ischemic attack), symptomatic pulmonary embolism or other clinically significant thromboembolic disease, or coronary artery bypass graft. * Clinically symptomatic bradycardia as assessed by the investigator. * Patients with other clinically significant cardiovascular disease who were assessed as unsuitable for this study by the investigator. 7. Patients who have a known diagnosis of Human Immunodeficiency Virus (HIV) infection or HIV antibody test positive in screening. 8. Patients with active hepatitis C or chronic hepatitis B at screening ("active hepatitis" defined as HCV RNA level ≥ 200 IU/mL for hepatitis C or HBV DNA level ≥ 2000 IU/mL for hepatitis B at screening). In addition, eligible hepatitis B or hepatitis C patients must agree to antiviral treatment according to the treatment guidelines. 9. Active infections requiring antibiotic intravenous therapy within 1 weeks prior to enrollment. 10. Moderate or severe hepatic impairment (Child-Pugh class B or C). 11. Patients who have not sufficient baseline organ function and whose laboratory data meet the following criteria at enrollment \[No transfusion of blood products (including platelets or red blood cells) or use of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days prior to screening\]: * Absolute Neutrophil Count (ANC) \< 1.5×109/L. * Total bilirubin \> 1.5×ULN. * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3×ULN without liver metastases or primary liver cancer. AST or ALT \> 5×ULN if the patient has documented liver metastases. * Hemoglobin \< 90 g/L. * Platelets \< 100×109 /L. * Creatinine clearance \< 30 mL/min. 12. Prior to first dose of the investigational product, received an antitumor drug or investigational drug at the following time intervals: * Chemotherapy, targeted small molecule therapy or radiotherapy (except palliative radiotherapy and the radiotherapy area do not include the proposed target lesion) ≤ 14 days. The wash-out period for TKI drugs is more than 5 half-lives could enroll for their shorter half-life. * Immunotherapy or cell therapy (i.e. chimeric antigen receptor T cell therapy) ≤ 28 days; Other cell therapy must be discussed with the investigators to determine eligibility. * Monoclonal antibodies ≤ 28 days for anticancer therapy. * Anti-tumor Chinese medicine which approved by the agency ≤ 14 days. * Immunosuppressive therapy for any reason ≤ 7 days. * Fulvestrant ≤ 250 days (5 half-lives). * All other investigational drugs or devices ≤ 28 days or 5 half-lives before the first dosing administration (whichever is shorter). 13. Bleeding constitution (e.g., diffuse intravascular coagulation \[DIC\], clotting factor deficiency), or long-term anticoagulant therapy (excluding antiplatelet therapy and low doses of warfarin and low molecular weight heparin). 14. Severe vascular embolism events requiring medical or surgical intervention. 15. Active autoimmune diseases that require systemic treatment (i.e. use of immunomodulators, corticosteroids, or immunosuppressive drugs). Note: Participants with hyperthyroidism/hypothyroidism could participate. Note: Hormone replacement therapy and symptomatic therapy (e.g., levothyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered a form of systemic therapy and are permitted. 16. Those who have received systemic corticosteroids within 4 weeks prior to administration of BL0175 or active control (low doses of corticosteroids are excluded, such as ≤ 20 mg prednisone daily or equivalent). 17. Those who underwent major surgery within 4 weeks before enrollment, or plan to undergo major surgery during the study. 18. Has not recovered from the toxic effects of prior treatment (including prior immunotherapy) and/or complications of surgical intervention to CTCAE v5.0 ≤ 1. Note: Participants with stable chronic AE (≤ grade 2) that are not expected to resolve on their own (e.g., peripheral neuropathy and alopecia) are allowed. 19. Those who are determined disqualified to join clinical studies by investigator for other causes.
Conditions Breast Cancer, Implant Breast Reconstruc...
Phase NA
Enrollment 534
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, randomized controlled, non-inferiority clinical trial designed to compare the outcomes of hypofractionated radiotherapy versus conventionally fractionated radiotherapy following mastectomy and implant-based breast reconstruction. The primary objective is to evaluate whether hypofractionated radiotherapy is non-inferior to conventionally fractionated radiotherapy regarding the rate of unplanned reoperation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: ConvRT — 50Gy/25Fx, 2Gy/Fx, once daily
  • Radiation: HypoRT — 42.56Gy/16Fx, 2.66Gy/Fx, once daily

Primary Outcomes

  • The rate of unplanned reoperation (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-10
Completion: 2035-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 534 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Jinli Ma, MD, PhD
+86-21-64175590
ma-jinli@outlook.com
Xiaofang Wang
86-21-64175590
xiaofang0708@yeah.net
Fudan University Shanghai Cancer Center
Interventions
  • Radiation: ConvRT — 50Gy/25Fx, 2Gy/Fx, once daily
  • Radiation: HypoRT — 42.56Gy/16Fx, 2.66Gy/Fx, once daily
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, 200032 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥ 18 years. * Pathologically confirmed unilateral primary invasive breast cancer. * Underwent skin-sparing (SSM) or nipple-sparing mastectomy (NSM) with axillary staging (sentinel lymph node biopsy or axillary lymph node dissection). * Underwent 1-stage (direct-to-implant) or 2-stage (tissue expander) reconstruction, or implant combined with autologous tissue, with prepectoral or subpectoral placement. * Received standard neoadjuvant or adjuvant systemic therapy (chemotherapy, endocrine, anti-HER2, or targeted therapy) according to guidelines or clinical trial protocols. * Definite indication for post-mastectomy chest wall ± regional nodal irradiation according to guidelines (typically c/pT1-3 N0-3 M0). * Interval of at least 6 weeks between reconstruction surgery and the initiation of radiotherapy. * ECOG performance status 0-1. * Prior non-breast malignancy permitted if disease-free for \> 5 years with low recurrence risk; prior cervical or colon carcinoma in situ, melanoma in situ, basal cell carcinoma, or squamous cell skin carcinoma permitted regardless of disease-free interval. * Estimated life expectancy ≥ 10 years. * Written informed consent provided. Exclusion Criteria: * Pregnant or lactating patients. * Prior history of breast cancer. * Bilateral breast cancer. * Prior radiotherapy to the ipsilateral chest wall or regional lymph node areas. * T4 disease (including, but not limited to, inflammatory breast cancer, regardless of response to neoadjuvant systemic therapy). * Non-breast malignancy within the past 5 years (except cervical or colon carcinoma in situ, melanoma in situ, basal cell carcinoma, or squamous cell skin carcinoma). * Severe non-malignant comorbidities (e.g., cardiovascular disease, pulmonary disease, systemic lupus erythematosus, or scleroderma) precluding radiotherapy tolerance or follow-up compliance.
Conditions Breast Cancer, Sentinel Lymph Node Biops...
Phase NA
Enrollment 1760
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn how to successfully introduce a new method for finding the sentinel lymph node during breast cancer surgery into routine hospital care. The method uses a dye called indocyanine green (ICG) and a special camera to see the lymph node. The sentinel lymph node is the first lymph node that cancer is likely to spread to. In the Netherlands, about 1 in 7 women develops breast cancer. Finding out whether cancer has spread to the lymph nodes is important for planning treatment and predicting outcomes. The current standard method for sentinel lymph node biopsy (SLNB) uses a radioactive tracer called radioisotope technetium-labeled (99mTc)-nanocolloid. While accurate, this method has several drawbacks: it exposes patients to radioactivity, requires an extra hospital visit or travel to another hospital due to limited nuclear medicine facilities, and is not sustainable. Surgeries using 99mTc can only take place on certain days due to logistical issues, and the signal from 99mTc can be disturbed by the tumor marker placed in the breast. ICG works as well as 99mTc for SLNB and offers several advantages: it is given during surgery (no extra visit needed), produces no radiation, and reduces costs. However, it is still not widely used in the Netherlands because hospitals may not be familiar with it or unsure how to make the switch. This study will introduce ICG step-by-step in several Dutch hospitals and evaluate how to make the change as smooth and effective as possible. It will take place in three stages: I) SLNB with 99mTc only (current practice); II) SLNB with both 99mTc and ICG (transition phase); III) SLNB with ICG only (full implementation). All study procedures take place during planned surgery, with no extra hospital visits. After surgery, participants will receive a short questionnaire (10-15 minutes) to share their experiences with the procedure. Their feedback, combined with input from healthcare providers, will help researchers develop a uniform medical protocol, an implementation guide, and educational materials for surgeons and surgical trainees. The aim is to make ICG widely available across the Netherlands, ensuring that care is less burdensome, more sustainable, and more cost-effective, while keeping treatment accessible in local hospitals.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Sequential Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Technetium (99mTc) — A radiopharmaceutical tracer consisting of technetium-99m (99mTc)-labelled nanocolloid used for sentinel lymph node mapping. In this study, 99mTc-nanocolloid is administered via periareolar injection with an activity of 40 MBq for the one-day protocol or 100 MBq for the two-day protocol, according to local hospital practice. Injection is performed either on the day of surgery or the afternoon before surgery. Preoperative lymphoscintigraphy is carried out to visualize lymphatic drainage. During surgery, a gamma-detection probe is used to locate and remove the sentinel lymph node(s) identified by 99mTc uptake.
  • Drug: Indocyanine Green — Indocyanine Green (ICG) is a fluorescent dye used for intraoperative sentinel lymph node mapping. In this study, a total dose of 5 mg (2 mL) of ICG is administered via periareolar injection after induction of general anesthesia and prior to axillary incision. During surgery, near-infrared fluorescence imaging is used to visualize lymphatic drainage and identify the sentinel lymph node(s). The identified node(s) are surgically removed under fluorescence guidance. In the transition phase, fluorescence findings are cross-checked against 99mTc uptake to ensure accuracy and safety.
  • Procedure: Sentinel lymph node biopsy — Sentinel lymph node biopsy (SLNB) is a surgical procedure used to identify and remove the first lymph node(s) that drain lymph from a tumor area. In this study, SLNB is performed through a small axillary incision after mapping the sentinel lymph node(s) using either radioisotope technetium-labeled (99mTc)-nanocolloid, indocyanine green (ICG) fluorescence imaging, or a combination of both. The identified lymph node(s) are excised and sent for pathological examination to determine the presence of cancer cells. The procedure is carried out under general anesthesia as part of breast cancer surgery.

Primary Outcomes

  • Adoption of ICG for sentinel lymph node biopsy (SLNB) (During Phase III, the post-implementation period, which is the final 9 months for hospitals in cluster 1, final 6 months for cluster 2, and final 3 months for cluster 3, within the 18-month trial.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-18
Completion: 2026-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1760 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Isabelle Henskens
Collaborators: Canisius-Wilhelmina Hospital, Spaarne Gasthuis, Noordwest Ziekenhuisgroep, Alrijne Hospital, Dijklander Ziekenhuis, Ziekenhuisgroep Twente, Diakonessenhuis, Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development
Principal Investigators:
  • Annemiek Doeksen, MD, PhD (PRINCIPAL_INVESTIGATOR) - St. Antonius Hospital
Contact Information
Study Contact:
Isabelle Henskens, MD
+31883202902
i.henskens@antoniusziekenhuis.nl
Annemiek Doeksen, MD, PhD
+3188 320 29 00.
a.doeksen@antoniusziekenhuis.nl
Gea Gooiker
+31725484160
borstkliniek-alkmaar@nwz.nl
Noordwest Ziekenhuisgroep
Interventions
  • Drug: Technetium (99mTc) — A radiopharmaceutical tracer consisting of technetium-99m (99mTc)-labelled nanocolloid used for sentinel lymph node mapping. In this study, 99mTc-nanocolloid is administered via periareolar injection with an activity of 40 MBq for the one-day protocol or 100 MBq for the two-day protocol, according to local hospital practice. Injection is performed either on the day of surgery or the afternoon before surgery. Preoperative lymphoscintigraphy is carried out to visualize lymphatic drainage. During surgery, a gamma-detection probe is used to locate and remove the sentinel lymph node(s) identified by 99mTc uptake.
  • Drug: Indocyanine Green — Indocyanine Green (ICG) is a fluorescent dye used for intraoperative sentinel lymph node mapping. In this study, a total dose of 5 mg (2 mL) of ICG is administered via periareolar injection after induction of general anesthesia and prior to axillary incision. During surgery, near-infrared fluorescence imaging is used to visualize lymphatic drainage and identify the sentinel lymph node(s). The identified node(s) are surgically removed under fluorescence guidance. In the transition phase, fluorescence findings are cross-checked against 99mTc uptake to ensure accuracy and safety.
  • Procedure: Sentinel lymph node biopsy — Sentinel lymph node biopsy (SLNB) is a surgical procedure used to identify and remove the first lymph node(s) that drain lymph from a tumor area. In this study, SLNB is performed through a small axillary incision after mapping the sentinel lymph node(s) using either radioisotope technetium-labeled (99mTc)-nanocolloid, indocyanine green (ICG) fluorescence imaging, or a combination of both. The identified lymph node(s) are excised and sent for pathological examination to determine the presence of cancer cells. The procedure is carried out under general anesthesia as part of breast cancer surgery.
Study Locations (7 sites)
Noordwest Ziekenhuisgroep, Alkmaar, Netherlands
Ziekenhuisgroep Twente, Hengelo, Netherlands
Spaarne Gasthuis, Hoofddorp, Netherlands
Dijklander Ziekenhuis, Hoorn, Netherlands
Alrijne Hospital, Leiden, Netherlands
Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands
Diakonessenhuis, Utrecht, Netherlands
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years old. * DCIS or invasive breast cancer, confirmed by biopsy * Clinically node-negative, confirmed by preoperative axillary ultrasound * Indication for breast cancer surgery with SLN procedure via axillar incision Exclusion Criteria: * Combined MARI procedure * Known allergy for Indocyanine Green (ICG), intravenous contrast or iodine * History of axillary lymph node dissection * Hyperthyroidism or thyroid cancer * Pregnancy or breast-feeding * No written informed consent according to ICH/GCP and national regulations.
Conditions Early Gastric Cancer, Advanced Gastric C...
Phase NA
Enrollment 414
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Standardized Telenursing — Within Smart Cancer Care Plus, predefined criteria are applied to trigger standardized telenursing interventions. When patients report symptoms of Grade 3 or higher severity, or when a scheduled weekly symptom report is not submitted within 48 hours of the designated reporting date, a structured telephone counseling session is initiated. This process is intended to ensure timely clinical follow-up, support appropriate self-management, and prevent the progression of unmanaged adverse events.
  • Other: Smart Cancer Care Plus — Smart Cancer Care Plus is a digital platform for patient-reported symptom monitoring and management, developed for individuals receiving chemotherapy. The system enables structured reporting of chemotherapy-related adverse events and provides standardized information regarding the severity grading of symptoms, accompanied by evidence-based self-management strategies. This intervention is intended to promote systematic symptom monitoring and to facilitate timely clinical responses to adverse events.

Primary Outcomes

  • Quality of life Measured by EORTC QLQ-C30 (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-09
Completion: 2026-09
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 414 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ulsan University Hospital
Collaborators: National Cancer Center, Korea, Kosin University Gospel Hospital, Gyeongsang National University Hospital, Gachon University Gil Medical Center
Principal Investigators:
  • Sujin Koh, Doctor of Philoshophy (PRINCIPAL_INVESTIGATOR) - Ulsan University Hospital
  • Keun Soek Lee, Doctor of Philoshophy (PRINCIPAL_INVESTIGATOR) - National Cancer Center, Korea
  • Sung Hoon Sim, Doctor of Philoshophy (PRINCIPAL_INVESTIGATOR) - National Cancer Center, Korea
Contact Information
Study Contact:
Minseon Song, bachelor's degree
+82522507018
9204564@uuh.ulsan.kr
Somin Joen, bachelor's degree
+82522301417
9204648@uuh.ulsan.kr
Kim
+8210-6227-6721
kimeunji514@naver.com
Kosin University Gospel Hospital
Interventions
  • Other: Standardized Telenursing — Within Smart Cancer Care Plus, predefined criteria are applied to trigger standardized telenursing interventions. When patients report symptoms of Grade 3 or higher severity, or when a scheduled weekly symptom report is not submitted within 48 hours of the designated reporting date, a structured telephone counseling session is initiated. This process is intended to ensure timely clinical follow-up, support appropriate self-management, and prevent the progression of unmanaged adverse events.
  • Other: Smart Cancer Care Plus — Smart Cancer Care Plus is a digital platform for patient-reported symptom monitoring and management, developed for individuals receiving chemotherapy. The system enables structured reporting of chemotherapy-related adverse events and provides standardized information regarding the severity grading of symptoms, accompanied by evidence-based self-management strategies. This intervention is intended to promote systematic symptom monitoring and to facilitate timely clinical responses to adverse events.
Study Locations (5 sites)
Kosin University Gospel Hospital, Busan, South Korea
National Cancer Center, Korea, Goyang, South Korea
Gachon University Gil Medical Center, Incheon, South Korea
Gyeongsang National University, Jinju, South Korea
Ulsan University Hospital, Ulsan, South Korea
Eligibility Criteria
Inclusion Criteria: * Adults aged 19 years or older * Diagnosed with early or advanced gastric, lung, breast, or colon cancer * Starting first-cycle chemotherapy with a new anticancer agent * Able to use a smartphone without difficulty * Willing to provide informed consent to participate in the study Exclusion Criteria: * Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons * Individuals who cannot read, write, or understand Korean * Other individuals deemed inappropriate for participation by the investigators
Conditions Locally Advanced Breast Cancer, Metastat...
Phase PHASE3
Enrollment 240
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-8080 Tablet — HRS-8080 tablet orally administered.
  • Drug: Fulvestrant injection — Fulvestrant injection.
  • Drug: Exemestane tablets — Exemestane tablets orally administered.
  • Drug: Everolimus Tablets — Everolimus tablets orally administered.
  • Drug: Anastrozole Tablets — Anastrozole tablets orally administered.
  • Drug: Letrozole Tablets — Letrozole tablets orally administered.

Primary Outcomes

  • Progression free survival (PFS) evaluated by the blinded independent central review (BICR). (Approximately 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-07-23
Completion: 2027-12
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shandong Suncadia Medicine Co., Ltd.
Contact Information
Study Contact:
Min Li
+86-0518-82342973
min.li.ml150@hengrui.com
Shusen Wang
13926168469
wangshs@sysucc.org.cn
Sun Yat-sen University Cancer Center
Wang Shusen
Sun Yat-sen University Cancer Center
Interventions
  • Drug: HRS-8080 Tablet — HRS-8080 tablet orally administered.
  • Drug: Fulvestrant injection — Fulvestrant injection.
  • Drug: Exemestane tablets — Exemestane tablets orally administered.
  • Drug: Everolimus Tablets — Everolimus tablets orally administered.
  • Drug: Anastrozole Tablets — Anastrozole tablets orally administered.
Study Locations (2 sites)
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510000 China
Hunan Cancer Hospital, Changsha, Hunan 410000 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18 to 75 years old (including both values). 2. ECOG Physical Strength Status (PS) : 0 to 1 point. 3. Patients with locally advanced or metastatic breast cancer confirmed by histology. 4. Patients previously received 1-2 lines of endocrine therapy. 5. Patients received no more than one line of chemotherapy in the recurrence/metastasis stage. 6. Menstrual status (meeting any of the following conditions) : a) After bilateral ovariectomy; b) Age ≥60 years old; c) Age \< 60 years old, natural menopause ≥12 months, without receiving chemotherapy, tamoxifen (TAM), tolemiphene or ovarian castration in the past year, follicle-stimulating hormone (FSH) and estradiol are within the postmenopausal range; d) For patients under the age of 60 who are taking TAM or tolemiphene, the levels of FSH and estradiol are within the postmenopausal range; e) Premenopausal or perimenopausal patients received luteinizing hormone-releasing hormone (LHRH) agonist treatment during the study period, and the treatment was initiated at least 14 days before the start of the study. 7. Patients comply with any of the following provisions of the RECIST v1.1 standard: a) There is at least one extracranial measurable lesion; b) If there are no measurable lesions as stipulated above, at least one osteolytic or mixed (osteolytic and osteogenic) bone lesion that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) exists. 8. Expected survival \> 6 months. 9. The functional level of the organs must meet the requirements. 10. Female with fertility must agree to use effective contraceptive measures for contraception during the study treatment period and within 7 months after the end of the study treatment period; Femalewith fertility must have a negative serum human chorionic gonadotropin (hCG) test within 7 days before enrollment in the study and must be in the non-lactation period. 11. Voluntarily participate in this clinical trial, be willing and able to abide by the procedures related to clinical visits and research, understand the research procedures and have signed the informed consent. Exclusion Criteria: 1. Patients previously received other systemic anti-tumor treatments besides chemotherapy、endocrine therapy and CDK4/6i (prior use of PI3K inhibitors or AKT inhibitors is permitted for patients with known PIK3CA mutations or PIK3CA/AKT/PTEN alterations). 2. Nitrosorea or mitomycin was received within 6 weeks before the first study administration in this study; Have undergone major organ surgery, cytotoxic drugs, immunotherapy, , anti-tumor traditional or Chinese medicine medications within 4 weeks before the first study administration and within 4 weeks or 5 half lives (whichever is shorter) prior to the first study drug administration ; Have received endocrine therapy (referring to aromatase inhibitors \[AI\], etc.) and palliative radiotherapy within 2 weeks before the first study administration. 3. the date from the first study administration to the last CYP3A4 strong inducer administration is less than 28 days. 4. Patients with rapid disease progression and investigators determines that endocrine therapy is not suitable or tolerant. 5. Patients with active (uncontrolled by medical treatment or with clinical symptoms) brain metastases, cancerous meningitis, spinal cord compression, or a history of primary central nervous system tumors; Patients with brain metastases who have completed treatment at least 28 days before the first study administration, have stable symptoms and do not require hormone therapy may be enrolled as appropriate, but they must be confirmed to have no cerebral hemorrhage by cranial imaging examinations such as CT, MRI or venography. 6. A history of severe clinical cardiovascular diseases. 7. Patients with uncontrollable tumor-related pain as judged by investigators. Patients who need pain-relieving medication must have a stable pain-relieving medication plan before entering the study. 8. Patients who have received immunosuppressant or systemic hormone therapy for immunosuppression within 2 weeks prior to the first medication (dose \> 10 mg/d prednisone or other corticosteroid hormones of equivalent physiological dose), excluding nasal sprays or inhaled hormones. 9. The damage caused by other treatments previously received by patients did not recover to grade ≤1 in the Common Terminology Criteria for Adverse Events of the National Cancer Institute of the United States, Version 5.0 (NCI CTCAE v5.0) (excluding alopecia and other adverse events judged tolerable by investigators). 10. Severe infection exists within 4 weeks before the first study administration, including but not limited to infectious complications requiring hospitalization, bacteremia, severe pneumonia, etc. There was an active infection of CTCAE grade ≥2 requiring intravenous antibiotic treatment within 2 weeks before the first study administration. 11. Patients with arterial/venous thrombotic events that occurred within 6 months before the first study administration, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc. 12. Patients with clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding. 13. Untreated active hepatitis. 14. Patients with other malignant tumors within the past 5 years or is currently suffering from them, except for cancers with an extremely low risk of recurrence, including but not limited to radical cervical carcinoma in situ, cutaneous basal cell carcinoma and squamous cell carcinoma, and surgically treated papillary thyroid carcinoma, etc. 15. Patients with hereditary or acquired bleeding tendency (such as hemophilia, coagulation dysfunction, etc.). 16. Patients with a history of active autoimmune diseases, immunodeficiency, or diseases and syndromes requiring systemic steroid hormone or immunosuppressive drug treatment, or having other acquired (human acquired immunodeficiency virus \[HIV\] infection), congenital immunodeficiency diseases, or a history of organ transplantation (including allogeneic bone marrow transplantation). 17. There is one of the multiple factors that affect oral medication (such as inability to swallow and intestinal obstruction, etc.) or there are active gastrointestinal diseases or other diseases that may lead to factors that significantly affect drug absorption, distribution, metabolism or excretion (active, inflammatory bowel disease or chronic diarrhea, enteral syndrome or upper gastrointestinal surgery, including gastrectomy). 18. Patients in the acute infection stage or active tuberculosis and requiring drug treatment. 19. Patients known to be allergic to the HRS-8080 component. 20. Pregnant and lactating women, or those planning to become pregnant during the study period. 21. Patients with a clear history of neurological or mental disorders, or patients with a history of drug abuse or psychotropic medication abuse. 22. Patients with other serious physical or laboratory examination abnormalities that may increase the risk of participating in the study, or interfere with the research results, as well as those deemed unsuitable for participation in the study by investigators.